Поиск микробных метаболитов — ингибиторов биосинтеза стеролов и противогрибковых антибиотиков
Диссертация
Для повышения эффективности поисковых исследований предложены новые подходы, направленные на усовершенствование методов работы с микробными продуцентами и образуемыми ими микробными метаболитами. Существующие микробиологические методы дополнены новыми современными методами культивирования микробных продуцентов и микробных тест-культур. Предложен новый подход к «активизации» микробных продуцентов… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ ОБЗОР ЛИТЕРАТУРЫ
- Микробный вторичный метаболизм и поиск биологически активных соединений
- Микробные метаболиты — ингибиторы биосинтеза стеролов (ИБС), их химическое разнообразие, особенности механизма действия
- Современные возможности противогрибковой терапии, основные направления в создании новых препаратов
- МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЙ И ИХ ОБСУЖДЕНИЕ
- ГЛАВА 1. Разработка методов поиска микробных метаболитов — ИБС и других биологически активных соединений
- 1. 1. Создание модели поиска на основе грибной культуры Асгетопшт иь idioid. es
- 1. 2. Бактериальная культура На1оЬас1ег'шт заИпагит как модель поиска ИБС
- 1. 3. Выявление гиполипидемической активности с использованием культуры человеческих злокачественных лимфобластов МОЕТ
- 1. 4. Оценка гиполипидемического действия и отбор активных соединений с использованием культуры клеток гепатобластомы в
- 1. 5. Новые подходы к работе с микроорганизмами — продуцентами и продуктами их жизнедеятельности, стимуляция продуцентов к образованию биологически активных метаболитов
Список литературы
- Автономова A.B., Краснопольская Л. М., Максимов В. Н. Оптимизация состава питательной среды для погружённого культивирования Ganoderma lucidum(Curt.:Fr.)P.Karst // Микробиология. 2006. т.75. — № 2. — С. 186−192.
- Баранова, H.A.- Крейер, В.Г.- Ландау, Н.С.- Егоров, Н. С. Метаболиты микромицетов ингибиторы роста и биосинтеза стеринов у дрожжей // Антибиотики и химиотерапия. — 2002. т.47. — № 1. — С.3−6.
- Бибикова М.В. Статины. Применение и перспективы // Фармацевтический вестник. 2003. — № 4. — С.30.
- Бибикова М.В., Бондарева Н. С. Препараты микробного происхождения для лечения атеросклероза // Антибиотики и химиотерапия. 1998. т.43. — № 8. -С.34−39.
- Бибикова М.В., Грамматикова Н. Э., Катлинский A.B. и др. Влияние природных гиполипидемических соединений на формирование биоплёнок штаммами рода Pseudomonas // Антибиотики и химиотерапия. 2009. т.54. -№ 1−2. — С.10−13. (а)
- Бибикова М.В., Грамматикова Н. Э., Катлинский A.B., Пужевская Т. О. Продуценты гиполипидемических соединений с антиоксидантной активностью // Антибиотики и химиотерапия. 2009. т.54. — № 7−8. — С.3−7. (Ь)
- Бибикова М.В., Грамматикова Н. Э., Тертов В. В. и др. Отбор природных иммуносупрессоров по способности к модификации синтеза стеролов клетками гепатоцитов // Антибиотики и химиотерапия. 2003. т.48. — № 8. -С.3−6.
- Бибикова М.В., Носик Д. Н., Лобыч O.A. и др. Влияние природных гиполипидемических соединений на вирус иммунодефицита человека // Антибиотики и химиотерапия. 2004. т.49. — № 1. — С. 14−16. (а)
- Бибикова М.В., Рыбакова A.M., Востров С. Н. и др. Система поиска природных иммуносупрессоров // Антибиотики и химиотерапия. 1991. -т.36. — № 3. -С. 17−20.
- Ю.Бибикова М. В., Чмель Я. В., Спиридонова И. А., Катлинский A.B.
- Бухман В.М., Трещалина Е. М., Краснопольская Л. М. и др. Получение и биологические свойства водных экстрактов и их композиций из мицелия базидиомицетов // Антибиотики и химиотерапия. 2007. т. 52. — № 1−2. -С.4−9.
- Гаузе Г. Ф., Преображенская Т. П., Свешникова М. А. и др. Определитель актиномицетов: роды Streptomyces, Streptoverticillium, Chainia. М.: Наука, 1983.-246 с.
- И.Гейл Э., Кандлифф Э., Рейнолдс П., Ричмонд М., Уоринг М. Молекулярные основы действия антибиотиков. М.: Мир, 1975. — 500 с.
- Грацианский H.A. Статины как противовоспалительные средства // Кардиология. 2001. — № 12. — С. 14−26.
- Грацианский Н. А. Уроки церивастатина и результаты исследования «Защита сердца» // Consilium medicum. 2003. — № 3. — С. 139−143.
- Егоров Н.С. Основы учения об антибиотиках. М.: Изд. МГУ, 2005. — 600 с.
- Егоров Н.С., Баранова H.A., Крейер В. Г. Микробные ингибиторы ферментов биосинтеза и этерификации холестерина // Антибиотики и химиотерапия. -1999. т.44. № 5. — С.38−43.
- Ершов Ю. В. Метилэритритолфосфатный (немевалонатный) путь биосинтеза изопреноидов. // Успехи биологической химии. 2005. — т. 45. — С.307—354.
- Ершов Ю. В. 2-с-метилэритритфосфатный путь биосинтеза изопреноидов как мишень при поиске новых антибиотиков, гербицидов и иммуномодуляторов (обзор) // Прикладная биохимия и микробиология. -2007. т.43. № 2. — С.133−157.
- Жукова P.A., Коммунарская А. Д., Пронина М. И. и др. Методы селекции продуцентов антибиотиков и ферментов Л.: Медицина, 1978. — 160 с.
- Захарова Т.М., Белова Т. С., Даниленко В. Н. Изучение влияния протопластирования на антибиотическую активность продуцента эритромицина // Антибиотики и химиотерапия. 1990. т.35. — № 1. — С.3−4.
- Исаева Л.М., Воейкова Т. А. Разработка системы протопластирования у штаммов Streptomyces aureofaciens продуцентов хлортетрациклина // Антибиотики и химиотерапия. — 1990. т.35. — № 12. — С.26−29.
- Катлинский A.B., Сазыкин Ю. О., Бибикова М. В., Орехов С. Н. Антифунгальные агенты. Новые предпосылки их создания и новые трудности // Антибиотики и химиотерапия. 2003. т.48. — № 9 — С.20−27.
- Климов А. Н., Нагорнев В. А. Взгляд на решение проблемы атеросклероза // Вестник Российской Академии медицинских наук. 1999. — № 9. — С.33−37.
- КлимовА.Н., Нагорнев В. А. Эволюция холестериновой концепции атерогене за: от Аничкова до наших дней // Медицинский Академический журнал -2001. т.1. № 3 — С.23−32.
- Крейер В.Г., Выборных С. Н., Баранова H.A., Егоров Н. С. Влияние ловастатина на синтез стеринов и резистентность дрожжей к полиеновым антибиотикам// Антибиотики и химиотерапия. 1993. т.38. — № 10. — С. 16−19.
- Ландау К.С., Баранова H.A., Крейер В. Г. и др. Действие ловастатина ингибитора синтеза стеринов на рост дрожжей // Микробиология. 1991. т. 60. — № 3.-С.479−484.
- Ланчини Д., Паренти Ф. Антибиотики. М.: Мир, 1985. — 272 с.
- Лаврентьева Г. И., Овсянко A.B. Использование метода протопластирования в селекции продуцента олеандомицина // Антибиотики и химиотерапия. -1990. т.35. № 4. — С. 17−20.
- Ломовская Н.Д. Генетика актиномицетов рода Streptomyces продуцентов биологически активных веществ. // В кн.: «Генетика промышленных микроорганизмов и биотехнология» — М.: Наука, 1990. — С.35−62.
- Люцканова Д.Г., Стоилова-Дишева М.М., Пелтекова В. Т. Увеличение продукции тилозина у производственного штамма Streptomyces fradiae II Прикладная биохимия и микробиология. 2005. т. 41. — № 2. — С. 189−193.
- Маланичева И.А., Козьмян Л. И., Белова А. Ю., Дудник Ю. В. Использование метода слияния и регенерации протопластов для поиска продуцентов антибиотиков среди неактивных штаммов стрептомицетов // Антибиотики и химиотерапия. 1993. т.38. — № 6. — С.8−11.
- Маланичева И.А., Козьмян Л. И., Дудник Ю. В. и др. Слияние протопластов штаммов Streptomyces fradiae, продуцентов неомицина и тилозина // Антибиотики и химиотерапия. 1992. т.37. — № 10. — С.3−7. (Ь)
- Потапов В.Д., Бахтеева И. В., Борзенков В. Н. и др. Действие фосмидомицина на развитие некоторых инфекций у мышей // Антибиотики и химиотерапия. 2003. т.48. — № 2. — С.9−12.
- Репин B.C., Смирнов В. Н. Фундаментальные науки против атеросклероза. -М., 1989.- 79 с.
- Сазыкин Ю.О., Бибикова М. В., Грамматикова Н. Э. и др. Механизм биологической активности макролидных антибиотиков — ингибиторов FoFl-АТФазы // Антибиотики и химиотерапия. 2003. т.48. -№ 12. — С.33−39.
- Сазыкин Ю.О., Бибикова М. В., Иванов В. П. и др. Технология скрининга вторичных микробных метаболитов: к эволюции методологии // Антибиотики и химиотерапия. 2002. т.47. — № 10. — С.25−31.
- Скала Л.З., Нехорошева А. Г., Винокуров А.Е, Лукин И. Н. Современные технологии в клинической микробиологии и химиотерапии.
- Автоматизированное рабочее место врача-микробиолога, химиотерапевта и эпидемиолога" // Клиническая лабораторная диагностика. 2001. — № 12. -С.25−32.
- Соловьева С.Е., Олсуфьева E.H., Преображенская М. Н. Химическое модифицирование противогрибковых макролидных полиеновых антибиотиков // Успехи химии. 2011, т.80. — № 2. — С.115−138.
- Степанова Е.В., Штиль A.A., Лавренов С. Н. и др. Соли трис(1-алкилиндол-3-ил)метилия новый класс противоопухолевых соединений // Известия Академии наук. Серия химическая. — 2010. — № 12. — С. 1 -9.
- Стоянова Л.Г. Новые бактериоцины лактококков и их практическое использование // Автореферат диссертации докт. биол. наук. М.: 2008.
- Стоянова Л. Г., Левина Н. В. Регуляция синтеза бактериоцина рекомбинантного штамма Lactococcus lactis subsp. ?actis F-116 компонентным составом среды // Микробиология. 2006. — т.75. — № 3. -С.286 -291.
- Стоянова Л.Г., Егоров Н. С., Фёдорова Г. Б. и др. Сравнение свойств бактериоцинов, образуемых штаммами Lactococcus lactis subsp. lactis разного происхождения II Прикладная биохимия и микробиология. 2007. — т. 43. — № 6. — С.677−684.
- Стоянова Л.Г., Сультимова Т. Д., Нетрусов А. И. Влияние фосфата и углеводов на синтез низина Lactococcus lactis subsp. lactis штамм 194 // Вестник Московского Университета, сер. Биология. 2003. Т. 16. — № 4. -С. 17−22.
- Страйер Jl. Биохимия. В 3-х томах. М.: Мир, 1984. — 940 с.
- Стулин И. Д., Белоусов Ю. Б., Лысейко Н. В. И др. Эволюция каротидного атеросклероза под влиянием терапии аторвастатином по данным дуплексного исследования // Журнал неврологии и психиатрии. 2007. т.107. — № 11. — С.31—35.
- Тренин A.C., Дудник Ю. В. Регенерация протопластов Nocardia orientalis // Антибиотики и химиотерапия. 1984. т.29. — № 7 — С.495−500.
- Тренин A.C., Катруха Г. С. Антибиотики ингибиторы биосинтеза холестерина // Хим.-фарм. ж-л. — 1997. т.31. — № 9. — С.5−16.
- Феофилова Е.П. Клеточная стенка грибов. М.: Наука, 1983. — 230 с.
- Чмель Я. В., Бибикова М. В., Спиридонова И. А. и др. Скрининг природных соединений с гиполипидемической активностью // Антибиотики и химиотерапия. 2004. т.49. — № 8−9. — С.8−12. (Ь)
- Шенин Ю.Д., Белахов В. В. Амфотерицин В: свойства, химическое строение, поиск производных // Антибиотики и химиотерапия. 1997. т.42. — № 4. -С.34−45.
- Шенин Ю.Д., Белахов В. В. Синтез и противогрибковая активность п-бензильных производных амфотерицина В // Хим.-фарм. ж-л. 2007. т. 42. -№ 7. — С.20−24.
- Agarwal В., Bhendwal S., Halmos B. et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells // Clin. Cancer Res.1999. V.5. N.8. — P.2223−2229.
- Ahern T.P., Pedersen L., Tarp M. et al. Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study // J. Natl. Cancer Inst. 2011 Aug 2. Epub. ahead of print. Режим доступа: www.ncbi.nlm.nih.gov/pubmed/21 813 413.
- Aliff T.B., Maslak P.G., Jurcic J.G. et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin // Cancer. 2003. V.97. — N.4. — P. 1025−1032.
- Alberts A.W., Chen J., Kuron G et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent // Proc. Natl. Acad. Sci. USA.- 1980. V.77. N.7. — P.3957−3961.
- Alksne L.E., Dunman P.M. Target-based antimicrobial drug discovery // Methods Mol. Biol.-2008. V.431. P.271−283.
- Amano S.I., Sakurai Т., Endo K. et al. A cryptic antibiotic triggered by monensin // J. Antibiot (Tokyo). 2011 — Jul 27. Epub. ahead of print. Режим доступа: www.ncbi.nlm.nih.gov/pubmed/21 792 210.
- Amet Т., Nonaka M., Dewan M.Z. et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for proteinprenylation in HIV-1 replication // Microbes Infect. 2008. V.10. — N.5. — P.471−480.
- Aminov R.I. The role of antibiotics and antibiotic resistance in nature // Environ. Microbiol.-2009. V. l 1. N.12. — P.2970−2988.
- Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future // Front. Microbiol. 2010. V. 1. — Article 134. — P. 1 -7.
- Anderson J.B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness // Nat. Rev. Microbiol. 2005. V.3. — N.7. — P.547−556.
- Aoki Y., Yoshihara F., Kondoh M. et al. Ro 09−1470 is a selective inhibitor of P-450 lanosterol C-14 demethylase of fungi // Antimicrob. Agents Chemother.-1993. V.37. N.12. — P.2662−2667.
- Aparicio J.F., Caffrey P., Gil J.A., Zotchev S.B. Polyene antibiotic biosynthesis gene clusters // Appl. Microbiol. Biotechnol. -2003. V.61. N.3. — P. 179−188.
- Arai M., Tomoda H., Okuda T. et al. Funicone-related compounds, potentiators of antifungal miconazole activity, produced by Talaromyces flavus FKI-0076 // J. Antibiot (Tokyo). 2002. V.55. — N.2. — P. 172−180.
- Assmus В., Urbich C., Aicher A. et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes // Circ Res. 2003. V.92. — N.9. — P. 1049−1055.
- Baginski M., Sternal K., Czub J., Borowski E. Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic // Acta Biochim. Pol. 2005. V.52. -N.3. — P.655−658.
- Balkis M.M., Leidich S.D., Mukherjee P.K., Ghannoum M.A. Mechanisms of fungal resistance: an overview//Drugs. -2002. V.62. -N.7. -P. 1025−1040.
- Baltz R.H., Stonesifer J. Phenotypic changes associated with loss of expression of tylosin biosynthesis and resistance genes in Streptomyces fradiae II J.Antibiot.(Tokyo). 1985. V.38. — N.9. — P.1226−1236.
- Baran M., Borowski E., Mazerski J. Molecular modeling of amphotericin B-ergosterol primary complex in water II // Biophys. Chem. 2009. V.141. — N.2−3. — P.162−168.
- Bellamine A., Mangla A.T., Dennis A.L. et al. Structural requirements for substrate recognition of Mycobacterium tuberculosis 14a-demethylase: implications for sterol biosynthesis // The Journal of Lipid Research. 2001. V.42. — P.128−136.
- Beltrametti F., Barucco D., Rossi R. et al. Protoplast fusion and gene recombination in the uncommon Actinomycete Planobispora rosea producing GE2270 // J. Antibiot (Tokyo). 2007. V.60. — N.7. — P.447−454.
- Bentley S.D., Chater K.F., Cerdeno-Tarraga A.M. et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2) // Nature. -2002. V.417. -N.6885. P. 141−147.
- Berrue F., Withers S.T., Haltli B. et al. Chemical screening method for the rapid identification of microbial sources of marine invertebrate-associated metabolites // Mar Drugs. -2011. V.9. N.3 — P.369−381.
- Blanc M., Hsieh W.Y., Robertson K.A. et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis // PLoS Biol.- 2011. V.9. N.3. — P. l-19. — Режим доступа: www.ncbi.nlm.nih.gov/pubmed/21 408 089.
- Blondelle S.E., Lohner K. Optimization and high-throughput screening of antimicrobial peptides // Curr. Pharm. Des. 2010. V. 16. — N.28. — P.3204−3211.
- Blows W.M., Foster G., Lane S.J. et al. The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma. V. Minor metabolites // J. Antibiot (Tokyo). 1994. V.47. — N.7. — P.740−754.
- Blum A., Simsolo C., Hasin Y. 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes // Atherosclerosis. 2004. V. 175. — N. 1. — P. 1−5.
- Blum D.J., Ко Y.H., Hong S. et al. ATP synthase motor components: proposal and animation of two dynamic models for stator function // Biochem. Biophys. Res. Commun. 2001. V.287. — N.4. — P.801−807.
- Bobek P., Hromadova M., Ozdin L. Oyster mushroom (Pleurotus ostreatus) reduces the activity of 3-hydroxy-3-methylglutaryl CoA reductase in rat liver microsomes // Experientia. 1995. V.51. -N.6. — P.589−591.
- Bode H.B., Bethe B., Hofs R., Zeeck A. Big effects from small changes: possible ways to explore nature’s chemical diversity // Chembiochem. 2002. V.3. — N.7. — P.619−627.
- Borgos S.E., Tsan .P, Sletta H. et al. Probing the structure-function relationship of polyene macrolides: engineered biosynthesis of soluble nystatin analogues // J. Med. Chem. 2006. V.49. — N.8. — P.2431 -2439.
- Borowski E. Novel approaches in the rational design of antifungal agents of low toxicity // Farmaco. 2000. V.55. — N.3. — P.206−208.
- Brady S.F., Bondi S.M., Clardy J. The guanacastepenes: a highly diverse family of secondary metabolites produced by an endophytic fungus // J. Am. Chem. Soc. 2001. V.123. — N40. — P.9900−9901.
- Brady S.F., Simmons L., Kim J.H., Schmidt E.W. Metagenomic approaches to natural products from free-living and symbiotic organisms // Nat. Prod. Rep. -2009. V.26. N. 11. — P. 1488−1503.
- Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action // Antimicrob. Agents Chemother. 1990. V.34. — N.2. — P. 183−188.
- Brautaset T., Sletta H., Nedal A. et al. Improved antifungal polyene macrolides via engineering of the nystatin biosynthetic genes in Streptomyces noursei II Chem. Biol.-2008. V.15. -N.l 1.-P.l 198−1206.
- Brotz-Oesterhelt H., Sass P. Postgenomic strategies in antibacterial drug discovery // Future Microbiol. 2010. V.5. — N. 10. — P. 1553−1579.
- Brouwer A.E., van Kan H.J., Johnson E. et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associatedcryptococcal meningitis // Antimicrob. Agents Chemother. 2007. V.51. — N.3. -P.1038−1042.
- Brown A. G., Smale T. C., King T. J. et al. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum II J. Chem. Soc. Perkin Trans. I. 1976. — P. l 165−1170.
- Brown M.S., Goldstein J. L. Atherosclerosis. Scavenging for receptors // Nature. 1990. V.343. -N.6258. — P.508−509.
- Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor // Cell. -1997. V.89. N.3. — P.331−340.
- Brusselmans K., Timmermans L., Van de Sande T. et al. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation // J. Biol. Chem. 2007. V.282. — N.26. — P. 18 777−18 785.
- Budzikiwicz H., Eckau H., Ehrenberg M. Bis (3-indolyl-)-3Hindolyliden-methan, ein von Saccharomyces cerevisiae Gebildeter Farbstoff. // Tetrahedron Lett. 1972. V.36. — P.3807−3810.
- Bugg T.D., Braddick D., Dowson C.G., Roper D.I. Bacterial cell wall assembly: still an attractive antibacterial target // Trends Biotechnol. 2011. V.29. -N.4. -P.167−173.
- Bui N.K., Turk S., Buckenmaier S. et al. Development of screening assays and discovery of initial inhibitors of pneumococcal peptidoglycan deacetylase PgdA // Biochem. Pharmacol. -2011. V.82. N.l.- P.43−52.
- Burton P.M., Swinney D.C., Heller R. et al. Azalanstat (RS-21 607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity // Biochem. Pharmacol. 1995. V.50. — N.4. — P.529−544.
- Byrne B., Carmody M., Gibson E. et al. Biosynthesis of deoxyamphotericins and deoxyamphoteronolides by engineered strains of Streptomyces nodosus II Chem. Biol. 2003. V. 10. — N. 12. — P. 1215−1224.
- Cabrera J.A., Bolds J., Shields P.E. et al. Isoprenoid synthesis in Halobacterium halobium. Modulation of 3-hydroxy-3-methylglutaryl coenzyme a concentration in response to mevalonate availability // J. Biol. Chem. 1986. V.261. — N8. — P.3578−3583.
- Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells // Carcinogenesis. 2005. V.26. — N.5. — P.883−891.
- Caffrey P., Aparicio J.F., Malpartida F., Zotchev S.B. Biosynthetic engineering of polyene macrolides towards generation of improved antifungal and antiparasitic agents // Curr. Top. Med. Chem. 2008. V.8. — N.8. — P.639−653.
- Calo D., Kaminski L., Eichler J. Protein glycosylation in Archaea: sweet and extreme // Glycobiology. 2010. V.20. — N.9. — P. 1065−1076.
- Cappelletty D., Eiselstein-McKitrick K. The echinocandins // Pharmacotherapy. 2007. V.27. — N.3. — P.369−388.
- Carrillo-Munoz A.J., Giusiano G., Ezkurra P.A., Quindos G. Antifungal agents: mode of action in yeast cells // Rev. Esp. Quimioter. 2006. V.19. — N.2. -P.130−139.
- Challis G.L., Hopwood D.A. Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by Streptomyces species // Proc. Natl. Acad. Sci. USA.- 2003. V.100. Suppl. 2. — P. 14 555−14 561.
- Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents // Clin. Cancer Res.-2003. V.9. N.l. — P.10−19.
- Chandrasekar P. Management of invasive fungal infections: a role for polyenes // J. Antimicrob. Chemother. 2011. V.66. — N.3. — P.457−465.
- Chapman S.W., Sullivan D.C., Cleary J.D. In search of the holy grail of antifungal therapy // Trans. Am. Clin. Climatol. Assoc. 2008. V. l 19. — P. 197 215.
- Charbonneau C., Fournier I., Dufresne S. et al. The interactions of amphotericin B with various sterols in relation to its possible use in anticancer therapy // Biophys. Chem. 2001. V.91. — N.2 — P. 125−133.
- Chen L., Liu W., Hu X. et al. Citrinin derivatives from the marine-derived fungus Penicillium citrinum II Chem. Pharm. Bull. (Tokyo). 2011. V.59. — N.4. — P.515−517. (a)
- Chen S.C., Slavin M.A., Sorrell T.C. Echinocandin antifungal drugs in fungal infections: a comparison // Drugs. 2011. V.71. — N.l. — P. l 1−41. (b)
- Chen X., Wei P., Fan L. et al. Generation of high-yield rapamycin-producing strains through protoplasts-related techniques // Appl. Microbiol. Biotechnol. -2009. V.83. -N.3. P.507−512.
- Cheng T.J., Wu Y.T., Yang S.T. et al. High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase // Bioorg. Med. Chem. 2010. V. l 8. — N.24. — P.8512−8529.
- Chu D.T., Plattner J.J., Katz L. New directions in antibacterial research // J. Med. Chem. 1996. V.39. — N.20. — P.3853−3874.
- Clatworthy A.E., Pierson E., Hung D.T. Targeting virulence: a new paradigm for antimicrobial therapy // Nat. Chem. Biol. 2007. V.3. — N.9. — P.541 -548.
- Clardy J., Fischbach M.A., Currie C.R. The natural history of antibiotics // Curr. Biol.-2009. V. 19. N. l 1. — P.437−441.
- Clardy J, Fischbach M. A, Walsh C.T. New antibiotics from bacterial natural products // Nat. Biotechnol. 2006. V.24 — N. 12. — P. 1541 -1550.
- Clerihew L., Austin N., McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review // Arch. Dis. Child. Fetal. Neonatal. Ed.-2008. V.93. -N.3. P. 198−200.
- Clinkenbeard K.D., Sugiyama T., Moss J. et al. Molecular and catalytic properties of cytosolic acetoacetyl coenzyme A thiolase from avian liver // J. Biol. Chem. 1973. V.248. -N.7. — P.2275−2284.
- Coates A.R., Hu Y. Novel approaches to developing new antibiotics for bacterial infections // Br. J. Pharmacol. 2007. V. 152. — N.8. — P. 1147−1154.
- Cochran K.W. Medicinal effects // In «The biology and cultivation of edible mushrooms» Eds. S.T.Chang, W. Hayes. New York: Academy Press, 1978. -P. 169−187.
- Corsini A., Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? // Curr. Med. Res. Opin. -2011. V.27. -N.8. P. 1551−1562.
- Cowen L.E., Anderson J.B., Kohn L.M. Evolution of drug resistance in Candida albicans // Annu. Rev. Microbiol. 2002. V.56. — P. 139−165.
- Craig W.Y., Cooper A.D. Effects of chylomicron remnants and (3-VLDL on the class and composition of newlly secreted lipopriteins by Hep G2 cells // J. Lipid Res. 1988. V.29. — P.299−308.
- Cuthbert J.A., Lipsky P.E. A product of mevalonate proximal to isoprenoids is the source of both a necessary growth factor and an inhibitor of cell proliferation // Trans. Assoc. Am. Physicians. 1991. V. 104. — P.97−106.
- Czub J., Baginski M. Modulation of amphotericin B membrane interaction by cholesterol and ergosterol a molecular dynamics study // J. Phys. Chem. B. -2006. V. l 10. -N.33. — P.16 743−16 753.
- Das A., Davis M.A., Tomoda H. et al. Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A//J. Biol. Chem. -2008. V.283. -N. 16. P. 10 453−10 460.
- Demain A.L., Adrio J.L. Strain improvement for production of pharmaceuticals and other microbial metabolites by fermentation // Prog. Drug. Res. 2008. V.65.- N.251. P.253−89.
- Demain A.L., Sanchez S. Microbial drug discovery: 80 years of progress. J. Antibiot (Tokyo). 2009. V.62. — N. 1. — P.5−16.
- DeVito J.A., Mills J.A., Liu V.G. et al. An array of target-specific screening strains for antibacterial discovery // Nat. Biotechnol. 2002. V.20. — N.5. — P.478−483.
- Dieting U., Trauthwein H., Zimmermann H. High-throughput screening in the climatic chamber // Elements Degussa Sei News. 2005. V. 11. — P. 14−18.
- Dimitroulakos J., Thai S., Wasfy G.H. et al. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias // Leuk. Lymphoma. 2000. V.40. — N. l-2. — P. 167−178.
- Donadio S., Maffioli S., Monciardini P. et al. Sources of novel antibiotics -aside the common roads // Appl. Microbiol. Biotechnol. 2010. V.88. — N.6. -P.1261−1267. (a)
- Donadio S., Maffioli S., Monciardini P. et al. Antibiotic discovery in the twenty-first century: current trends and future perspectives // J. Antibiot (Tokyo).- 2010. V.63. N.8. — P.423−430. (b)
- Dothager R.S., Putt K.S., Allen B.J. et al. Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest // J. Am. Chem. Soc. 2005. V.127. — N.24. — P.8686−8696.
- Dougherty T.J., Barrett J.F., Pucci M.J. Microbial genomics and novel antibiotic discovery: new technology to search for new drugs // Curr. Pharm. Des. -2002. V.8. -N. 13. P. 1119−1135.
- Duetz W.A., Witholt B. Effectiveness of orbital shaking for the aeration of suspended bacterial cultures insquare-deepwell microtiter plates // Biochem. Eng. J.-2001. V.7.-P.113−115.
- Dufresne C., Wilson K.E., Singh S.B. et al. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase // J. Nat. Prod. 1993. V.56. — N. 11. — P. 1923−1929.
- Eichler J. Facing extremes: archaeal surface-layer (glyco)proteins // Microbiology. 2003. V. 149. — N. 12. — P.3347−3351.
- Eichler J., Adams M.W. Posttranslational protein modification in Archaea // Microbiol. Mol. Biol. Rev. 2005. V.69. — N.3. — P.393−425.
- Eichler J., Maupin-Furlow J., Soppa J. Archaeal protein biogenesis: posttranslational modification and degradation // Archaea. 2010. Sep 30. — pii: 643 046. — Режим доступа: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948886.
- Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase // J. Antibiot (Tokyo). -1980. V.33. N.3. — P.334−336.
- Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase // J. Med. Chem. -1985. V.28. N.4. — P.401 -405.
- Endo A., Hasumi K., Negishi S. Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber H J. Antibiot (Tokyo). -1985. V.38. -N.3. -P.420−422. (a)
- Endo A., Hasumi K., Yamada A. et al. The synthesis of compactin (ML-236B) and monacolin K in fungi // J. Antibiot (Tokyo). 1986. V.39. — N. 11. — P. 16 091 610.
- Endo A., Kuroda M. Citrinin, an inhibitor of cholesterol synthesis // J. Antibiot (Tokyo). 1976. V.29. — N.8. — P.841−843.
- Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium // J. Antibiot (Tokyo). 1976. v.29. -N.12. — P. 1346−1348.
- Endo A., Negishi Y., Iwashita T. et al. Biosynthesis of ML-236B (compactin) and monacolin K // J. Antibiot (Tokyo). 1985. V.38. -N.3. — P444−448. (b)
- Endo A., Yamashita H., Naoki H. et al. Microbial phosphorylation of compactin (ML-236B) and related compounds // J. Antibiot (Tokyo). 1985. V.38. — N.3. — P.328−332. (c)
- Espinel-Ingroff A. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005−2009) // Rev. Iberoam. Micol. 2009. V.26. — N. 1. — P. 15−22.
- Fajardo A., Martinez J.L. Antibiotics as signals that trigger specific bacterial responses // Curr. Opin. Microbiol. 2008. V. l 1. -N.2. — P. 161 -167.
- Farese R.V. Jr. The nine lives of ACAT inhibitors // Arterioscler. Thromb. Vase. Biol.-2006. V.26.-N.8. P. 1684−1686.
- Faust J., Krieger M. Expression of specific high capacity mevalonate transport in a Chinese hamster cell variant // J. Biol. Chem. 1987. V.262. — N.5. — P. 19 962 004.
- Ferrand S., Tao J., ShenX. et al. Screening for mevalonate biosynthetic pathway Inhibitors using sensitized bacterial strains // J. Biomol. Screen. 2011. V.16. — N.6. — P.637−46.
- Fischbach M.A., Clardy J. One pathway, many products // Nat. Chem. Biol. -2007. V.3. N.7. — P.353−355.
- Fitch M.E., Mangels A.R., Altmann W.A., El Hawary M., Qureshi A.A., and Elson C.E. Microbiological screening of mevalonate-suppressive minor plant constituents // J. Agric. Food Chem. 1989. V.37. — P.687−691.
- Freire-Moran L., Aronsson B., Manz C. et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now // Drug Resist. Updat. 2011. V. 14. — N.2. — P. 118−124.
- Fukuda T., Hasegawa Y., Hagimori K. et al. Tensidols, new potentiators of antifungal miconazole activity, produced by Aspergillus niger FKI-2342 // J. Antibiot (Tokyo). 2006. V.59. — N.8. — P.480−485.
- Fukuda T., Hasegawa Y., Sakabe Y. et al. Citrinamides, new potentiators of antifungal miconazole activity, produced by Penicillium sp. FK1−1938 // J. Antibiot (Tokyo). 2008. V.61. — N.9. — P.550−555.
- Fukuda T., Matsumoto A., Takahashi Y., et al. Phenatic acids A and B, new potentiators of antifungal miconazole activity produced by Streptomyces sp. K03−0132// J. Antibiot (Tokyo). 2005. V.58. — N.4. — P.252−259. (a)
- Gauthaman K., Fong C.Y., Bongso A. Statins, stem cells, and cancer // J. Cell Biochem. 2009. V. 106. — N.6. — P.975−983.
- Genilloud O., Gonzalez I., Salazar O. et al. Current approaches to exploit actinomycetes as a source of novel natural products // J. Ind. Microbiol. Biotechnol. 2011. V.38. — N.3. — P.375−389.
- Georgopapadakou N.H., Bertasso A. Effects of squalene epoxidase inhibitors on Candida albicans // Antimicrob. Agents Chemother. 1992. V.36. N.8. -P.1779−1781.
- Gillespie D.E., Brady S.F., Bettermann A.D. et al. Isolation of antibiotics turbomycin a and B from a metagenomic library of soil microbial DNA // Appl. Environ. Microbiol. 2002. V.68. — N.9. — P.4301−4306.
- Girmenia C., Martino P. New antifungal drugs and new clinical trials: interpreting results may be difficult // Curr. Opin. Oncol. 2003. V.15. — N.4. -P.283−288.
- Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway // Nature. -1990. V.343. -N.6257. P.425−430.
- Gower T.L., Graham B.S. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro // Antimicrob. Agents Chemother. 2001. V.45. -N.4. — P. 1231−1237.
- Haendeler J., Hoffmann J., Diehl J.F. et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells // Circ. Res. 2004. V.94. — N.6. — P.768−775.
- Hamano Y., Dairi T., Yamamoto M. et al. Growth-phase dependent expression of the mevalonate pathway in a terpenoid antibiotic-producing streptomyces strain // Bioscience Biotechnol. Biochemistry. 2002. V.66. — N.4. — P.808−819.
- Handelsman J. Metagenomics: application of genomics to uncultured microorganisms // Microbiol. Mol. Biol. Rev. 2004. V.68. — N.4. — P.669−685.
- Hasumi K., Arahira M., Sakai K., Endo A. Irreversible inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by phenicin (phoenicine) // J. Antibiot (Tokyo). 1987. V.40. — N.2. — P.224−226.
- Hatori H., Sato B" Sato I. et al. FR901512, a novel HMG-CoA reductase inhibitor produced by an agonomycetous fungus no. 14 919. II. Biological profiles // J. Antibiot (Tokyo). 2004. V.57. — N.6. — P.390−393. (b)
- Hatori H., Shibata T., Nishikawa M. et al. FR171456, a novel cholesterol synthesis inhibitor produced by Sporormiella minima No. 15 604. II. Biological activities // J. Antibiot (Tokyo). 2004. V.57. — N.4. — P.260−263. (c)
- Haustedt L.O., Mang C., Siems K., Schiewe H. Rational approaches to natural-product-based drug design // Curr. Opin. Drug Discov. Devel. 2006. V.9. — N.4. — P.445−462.
- Hayes M. V. The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma. 1. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity // J. Antibiot (Tokyo). 1992. V.45. — N.5. -P.639−647.
- Hendrickson L., Davis C.R., Roach C. et al. Lovastatin biosynthesis in Aspergillus terreus: characterization of blocked mutants, enzyme activities and a multifunctional polyketide synthase gene // Chem. Biol. 1999. V.6. — N.7. -P.429−439.
- Herbrecht R., Denning D.W., Patterson T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis // N. Engl. J. Med. -2002. V.347. N.6. — P.408−415.
- Hindier K., Cleeland C.S., Rivera E., Collard C.D. The role of statins in cancer therapy // Oncologist. 2006. V. l 1. — N.3. — P.306−315.
- Hong S., Pedersen P.L. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas // Microbiol. Mol. Biol. Rev. -2008. V.72.-N.4.-P.590−641.
- Hopwood D.A. Genetic studies with bacterial protoplasts // Annu. Rev. Microbiol. 1981. V.35.-P.237−272.
- Hopwood D.A. Forty years of genetics with Streptomyces: from in vivo through in vitro to in silico // Microbiology. 1999. V.145. — N.9. — P.2183−2202.
- Hopwood DA. Cracking the polyketide code // PLoS Biol. 2004. V.2. — N.2. — E35. — P.0166−0169. — Режим доступа: 10.1371/journal.pbio.20 035 -PMID: 14 966 534.
- Hopwood D.A., Bibb M., Chater K.F. et al. Genetic manipulation of Streptomycetes. A laboratory manual. Norwich, UK: The John Innes Foundation, 1985. — 68p.
- Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver // J. Clin, invest. -2002. V. 109. N.9. — P. l 125−1131.
- Hosokawa Т., Suzuki K., Okutomi T. et al. Effect of ascofuranone on serum lipids of rats fed a cholesterol rich diet // Jpn. J. Pharmacol. 1975. V.25. — N.l. -P.35−39.
- Hu Y., Shamaei-Tousi A., Liu Y., Coates A. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections // PLoS One. 2010. V.5. — N.7. — P. el 1818.
- Ikeura R., Murakawa S., Endo A. Growth inhibition of yeast by compactin (ML-236B) analogues // J. Antibiot (Tokyo). 1988. V.41. — N.8. — P. l 148−1150.
- Inoue M., Nakada M. Structure elucidation and enantioselective total synthesis of the potent HMG-CoA reductase inhibitor FR901512 via catalytic asymmetric Nozaki-Hiyama reactions // J. Am. Chem. Soc. 2007. V.129. — N. l4. — P.4164−4165.
- Issat Т., Nowis D., Legat M. et al. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo // Int. J. Oncol. -2007. v.30. -N.6. -P.1413−1425.
- Iwasaki S., Omura S. Search for protein farnesyltransferase inhibitors of microbial origin: our strategy and results as well as the results obtained by other groups // J. Antibiot (Tokyo). 2007. v.60. — N. 1. — P. 1 -12.
- Jiang H., Hutchinson C.R. Feedback regulation of doxorubicin biosynthesis in Streptomyces peucetius H Res. Microbiol. 2006. V.157. — N.7. — P.666−674.
- Jiang Z., Zheng X., Lytle R.A. et al. Lovastatin-induced up-regulation of the ВНЗ-only protein, Bim, and cell death in glioblastoma cells // J. Neurochem. -2004. V.89. -N.l. P. 168−178.
- Joly V., Bolard J., Yeni P. In vitro models for studying toxicity of antifungal agents // Antimicrob. Agents Chemother. 1992. V.36. — N.9. — P. 1799−1804.
- Jones C.A., Sidebottom P.J., Cannell R.J. et al. The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma. III. Biosynthesis // J. Antibiot (Tokyo). 1992. V.45. — N9. — P. 1492−1498.
- Joshua H., Schwartz M.S., Wilson K.E. L-669,262, a potent HMG-CoA reductase inhibitor//J. Antibiot (Tokyo). 1991. V.44. — N.3. — P.366−3 70.
- Joubert A., Calmes B., Berruyer R. et al. Laser nephelometry applied in an automated microplate system to study filamentous fungus growth // Biotechniques. 2010. V.48. — N.5. — P.399−404.
- Kadam S., Poddig J., Humphrey P. et al. Citrinin hydrate and radicinin: human rhinovirus 3C-protease inhibitors discovered in a target-directed microbial screen // J. Antibiot (Tokyo). 1994. V.47. — N.7. — P.836−839.
- Kahan B.D. Forty years of publication of transplantation proceedings—the second decade: the cyclosporine revolution // Transplant. Proc. -2009. V.41. -N.5. P.1423−1437.
- Kahlon A.K., Roy S., Sharma A. Molecular docking studies to map the binding site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus aureus // J. Biomol. Struct. Dyn. -2010. V.28. N.2. — P.201−210.
- Kamigaki M., Sasaki T., Serikawa M. et al. Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells // Int. J. Oncol. -2011. V.39. N.3. -P.561−568.
- Kasai Y., Matsumori N., Umegawa Y. et al. Self-assembled amphotericin B is probably surrounded by ergosterol: bimolecular interactions as evidenced by solid-state NMR and CD spectra // Chemistry. -2008. V.14. N.4. — P. 11 781 185.
- Kato J.Y., Funa N., Watanabe H. et al. Biosynthesis of gamma-butyrolactone autoregulators that switch on secondary metabolism and morphological development in Streptomyces // Proc. Natl. Acad. Sci. USA.- 2007. V.104. -N.7. P.2378−2383.
- Kaufman D.A. Prevention of invasive Candida infections in preterm infants: the time is now // Expert Rev. Anti Infect. Ther. 2008. V.6. — N.4. — P.393−399.
- Kaufman D.A., Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants // Clin. Perinatol. 2010. V.37. — N.3. — P.611−628.
- Kawashima A., Nakamura Y., Ohta Y. et al. New cholesterol biosynthesis inhibitors MC-031 (O-demethylchlorothricin), -032 (O-demethylhydroxychlorothricin), -033 and -034 // J. Antibiot (Tokyo).- 1992. V.45. N.2. — P.207−212.
- Kleinkauf H., von Dohren H. Linking peptide and polyketide biosynthesis // J. Antibiot (Tokyo). 1995. V.48. -N.7. — P.563−567.
- Klimov A.N., Nagornev V.A. Evolution of cholesterol concept of atherogenesis from Anitchkov to our days // Pediatr. Pathol. Mol. Med. 2002. V.21. — N.3. — P.307−320.
- Kluepfel D., Surendra N., Vezina S., Vezina C. Antimycin A components. 1. Isolation and biological activity // J. Antibiotics (Tokyo). 1970. V.23. — N.2. -P.75−80.
- Kobayashi K., Nishino C., Ohya J. et al. Oligomycin E, a new antitumor antibiotic produced by Streptomyces sp. MCI-2225 // J. Antibiot (Tokyo). 1987. V.40. — N.7. — P.1053−1057.
- Koehn F.E. High impact technologies for natural products screening // Prog. Drug Res. 2008. V.65. — P. 177−210.
- Koehn F. E, Carter G.T. Rediscovering natural products as a source of new drugs // Discov. Med. 2005. V.5. — N26. — P. 159−164.
- Komagata D., Yamashita H., Endo A. Microbial conversion of compactin (ML-236B) to ML-236A // J. Antibiot (Tokyo). 1986. V.39. — N.ll. — P. 15 741 577.
- Kotowska M. Application of molecular biology for the discovery of biosynthetic genes of polyketide and peptide antibiotics produced by actinomycetes // Postepy Biochem. 2005. V.51. — N.3. — P.345−352.
- Kuchta T., Leka C., Farkas P. et al. Inhibition of sterol 4-demethylation in Candida albicans by 6-amino-2-n-pentylthiobenzothiazole, a novel mechanism ofaction for an antifungal agent // Antimicrob. Agents Chemother. 1995. V.39. -N.7. -P.1538−1541.
- Kuhnt D., Anke T., Besl H. et al. Antibiotics from basidiomycetes. XXXV11. New inhibitors of cholesterol biosynthesis from cultures of Xerula melanotricha Dorfelt // J. Antibiot (Tokyo). 1990. V.43. — N. 11. — P. 1413−1420.
- Kumagai H., Tomoda H., Omura S. Method of search for microbial inhibitors of mevalonate biosynthesis using animal cells // J. Antibiot (Tokyo). 1990. V.43. — N.4. — P.397−402.
- Kumagai H., Tomoda H., Omura S. Biosynthesis of antibiotic 1233A (F-244) and preparation of 14C.1233A // J. Antibiot (Tokyo). 1992. V.45. — N.4. -P.563−567.
- Kuroda M., Endo A. Inhibition of in vitro cholesterol synthesis by fatty acids // Biochim. Biophys. Acta. 1976. V.486. — N. 1. — P.70−81.
- Kurtz M.B., Douglas C., Marrinan J. et al. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis // Antimicrob. Agents Chemother. 1994. V.38. -N.12. — P.2750−2757.
- Kuzuyama T. Mevalonate and nonmevalonate pathways for the biosynthesis of the isoprenoid units // Biosci. Biotechnol. Biochem. 2002. V.166. — N.8. -P.1619−1627.
- Laatsch H., Kellner M., Wolf G. et al. Oligomycin F, a new immunosuppressive homologue of oligomycin A // J. Antibiot (Tokyo). 1993. V.46. — N.9. — P. 1334−1341.
- Laezza C., Fiorentino L., Pisanti S. et al. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state //J. Mol. Med. (Berl). 2008. V.86. — N.12. — P.1341−1351.
- Lancini G., Parenti F., Gallo G.G. Antibiotics a multidisciplinary approach. -New York: Plenum Press, 1995. — 278p.
- Lavrenov S.N., Luzikov Y.N., Bykov E.E. et al. Synthesis and cytotoxic potency of novel tris (l-alkylindol-3-yl)methylium salts: role of N-alkyl substituents // Bioorg. Med. Chem. 2010. V.18. -N.18. — P.6905−6913.
- Lee T.J., Holtz W.J., Smith R.L. et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 8. Side chain ether analogues of lovastatin // J. Med. Chem. 1991. V.34. — N.8. — P.2474−2477.
- Leeds J.A., Schmitt E.K., Krastel P. Recent developments in antibacterial drug discovery: microbe-derived natural products—from collection to the clinic // Expert. Opin. Investig. Drugs. -2006. V.15. -N.3. P.211−226.
- Leon C., Hill J.S., Wasan K.M. Potential role of acyl-coenzyme A: cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs // Pharm. Res. 2005. V.22. -N.10. — P. 1578−1588.
- Lepesheva G.I., Ott R.D., Hargrove T.Y. et al. Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth // Chem. Biol. 2007. V. 14. — N. 11. — P. 1283−1293.
- Lepesheva G.I., Waterman M.R. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms // Biochim. Biophys. Acta. 2007. V. 1770. — N.3. — P.467−477.
- Lepre F., Campbell B., Crane S., Hickman P. Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein (a) // Am. J. Cardiol. 1992. V.70. — N. 1. -P.133.
- Letscher-Bru V., Herbrecht R. Caspofungin: the first representative of a new antifungal class // J. Antimicrob. Chemother. 2003. V.51. — N.3. — P.513−521.
- Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier? // Science. 2009. V.325. — N.5937. — P. 161−165.
- Li Y.C., Fung K.P., Kwok T.T. et al. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells // Chemotherapy. 2004. V.50. — N.2. — P.55−62.
- Lindsey S., Harwood H.J. Jr. Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation // J. Biol. Chem. 1995. V.270. -N.16. — P.9083−9096.
- Liu C.I., Liu G.Y., Song Y. et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence // Science. 2008. V.319. — N.5868. — P. 1391 -1394.
- Liu S., Rodriguez A.V., Tosteson M.T. Role of simvastatin and methyl-beta-cyclodextrin corrected. on inhibition of poliovirus infection // Biochem. Biophys. Res. Commun. 2006. V.347. — N. 1. — P.51 -59.
- Livermore D.M. Discovery research: the scientific challenge of finding new antibiotics // J. Antimicrob. Chemother. 2011. V.66. — N.9. — P. 1941 -1944.
- Lombo F., Menendez N., Salas J.A., Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives // Appl. Microbiol. Biotechnol. 2006. V.73. -N.l. — P. 1−14.
- Lopez-Martinez R. Candidosis, a new challenge // Clin. Dermatol. 2010. V.28. — N.2. — P. 178−184.
- Lowry O.H., Rosebrough N.J., Farr A.L., Randall N.J. Protein measurement with the Folin phenol reagent// J. Biol. Chem. 1951. V. 193. — N. l — P.265−275.
- Luo Y., Ding X., Xia L. et al. Conditions for protoplast preparation of spinosyn-producing strain and the physiological properties of protoplast-regenerated strains. // Sheng Wu Gong Cheng Xue Bao. 2009. V.25. — N.3.-P.360−367.
- Luttgen, H., Rohdich, F., Herz, S. et al. Biosynthesis of terpenoids: YchB protein of Escherichia coli phosphorylates the 2-hydroxy group of diphosphocytidyl-2C-methyl-D-erythritol II Proc. Natl. Acad. Sei. U.S.A. 2000. V. 97.-N.3. — P. 1062−1067.
- Lysenkova L.N., Turchin K.F., Danilenko V.N. et al. The first examples of chemical modification of oligomycin A // J. Antibiot (Tokyo). -2010. V.63. -N.l. P.17−22.
- Ma S.M., Li J.W., Choi J.W. et al. Complete reconstitution of a highly reducing iterative polyketide synthase // Science. 2009. V.326. — N.5952. -P.589−592.
- Magae J., Hosokawa T., Ando K. et al. Antitumor protective property of an isoprenoid antibiotic, ascofuranone // J. Antibiot (Tokyo). 1982. V.35. — N. l 1. -P.1547−1552.
- Magae J., Nagai K., Ando K. et al. Effects of an antitumor agent, ascofuranone, on the macromolecular syntheses of intact cells // J. Antibiot (Tokyo). 1983. V.36. — N.7. — P.892−899.
- Magae J., Nagai K., Suzuki S. et al. Macrophage-specific effect on lipid metabolism by an antibiotic, ascofuranone // J. Antibiot (Tokyo). 1987. V.40. -N.2. — P.202−208.
- Magae J., Suzuki S., Nagai K. et al. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system // Cancer Res. 1986. V.46. — N.3. -P.1073−1078. (b)
- Magiorakos A.P., Suetens С., Boyd L. et al. National hand hygiene campaigns in Europe, 2000−2009 // Euro Surveill. 2009. V.14. — 1.17. — art.5 — Режим доступа: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 19 190.
- Magi его wska-Jung M., Cefa’i D., Marrakchi H. et al. In vitro determination of antiviral activity of MS8209, a new amphotericin В derivative, against primary isolates of HIV 1 //Res. Virol. 1996. V.147.-N.5.-P.313−318.
- Malina H., Tempete C., Robert-Gero M. Enhanced sinefungin production by medium improvement, mutagenesis, and protoplast regeneration of Streptomyces incarnatus NRRL 8089 // J. Antibiot (Tokyo). 1985. V.38. — N.9. — P. 12 041 210.
- Marcone G.L., Carrano L., Marinelli F., Beltrametti F. Protoplast preparation and reversion to the normal filamentous growth in antibiotic-producing uncommon actinomycetes // J. Antibiot (Tokyo). 2010. V.63. — N.2. — P.83−88.
- Marr K. Combination antifungal therapy: where are we now, and where are we going?//Oncology. 2004. V.18. -N.13. — Suppl. 7. — P.24−29.
- Martinez L.R., Ntiamoah P., Casadevall A., Nosanchuk J.D. Caspofungin reduces the incidence of fungal contamination in cell culture // Mycopathologia. -2007. V.164. N.6. P.279−286.
- Marwali M.R., Rey-Ladino J., Dreolini L. et al. Membrane cholesterol regulates LFA-1 function and lipid raft heterogeneity // Blood. 2003. V. 102. — N. 1. — P.215−222.
- Mathew B.P., Nath M. Recent approaches to antifungal therapy for invasive mycoses // Chem. Med. Chem. 2009. V.4. — N.3. — P.310−323.
- Matsukuma S., Ohtsuka T., Kotaki H. et al. A new series of natural antifungals that inhibit P450 lanosterol C-14 demethylase. I. Taxonomy, fermentation, isolation and structural elucidation // J. Antibiot (Tokyo). 1992. V.45. — N.2. -P.151−159.
- Matsumori N., Sawada Y., Murata M. Large molecular assembly of amphotericin В formed in ergosterol-containing membrane evidenced by solidstate NMR of intramolecular bridged derivative // J. Am. Chem. Soc. 2006. V.128. — N.36. — P. l 1977−11 984.
- Matsuoka S., Ikeuchi H., Umegawa Y. et al. Membrane interaction of amphotericin В as single-length assembly examined by solid state NMR for uniformly 13C-enriched agent // Bioorg. Med. Chem. -2006. V.14. N.19. -P.6608−6614.
- Mazerski J., Bolard J., Borowski E. Effect of the modifications of ionizable groups of amphotericin В on its ability to form complexes with sterols in hydroalcoholic media//Biochim. Biophys. Acta. 1995. V.1236. — N.l. — P. 170 176.
- McAnally J.A., Gupta J., Sodhani S. et al. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo // Exp. Biol. Med. 2007. V.232. — N.4. — P.523−531.
- Mejia A., Barrios-Gonzalez J., Viniegra-Gonzalez G. Overproduction of rifamycin В by Amycolatopsis mediterranei and its relationship with the toxic effect of barbital on growth//J. Antibiot (Tokyo). 1998. V.51.-N.l. — P.58−63.
- Meletiadis J., Meis J.F., Mouton J.W., Verweij P.E. Analysis of growth characteristics of filamentous fungi in different nutrient media // J. Clin. Microbiol. 2001. V.39. — N.2. — P.478−484.
- Mendez C., Kunzel E., Lipata F. et al. Oviedomycin, an unusual angucyclinone encoded by genes of the oleandomycin-producer Streptomyces antibioticus ATCC11891 // J. Nat. Prod. 2002. V.65. — N.5. — P.779−782.
- Menys V.C., Durrington P.N. Squalene synthase inhibitors // Br. J. Pharmacol.- 2003. V.139. -N.5. -P.881−882.
- Metcalf S.C., Dockrell D.H. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts // J. Infect. -2007. V.55. N.4. — P.287−299.
- Middleton R.F., Foster G., Cannell R.J. et al. Novel squalestatins produced by biotransformation // J. Antibiot (Tokyo). 1995. V.48. — N.4. — P.311 -316.
- Minowada J., Onuma T., Moore G.E. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes // J. Natl. Cancer Inst. 1972. V.49. — N.3. — P.891−895.
- Mistefa O., Stenius U. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells // Biochem. Pharmacol. 2009. V.78. — P. l 115−1126.
- Mitsuguchi H., Seshime Y., Fujii I. et al. Biosynthesis of Steroidal Antibiotic Fusidanes: Functional Analysis of Oxidosqualene Cyclase and Subsequent Tailoring Enzymes from Aspergillus fumigates II J. Am. Chem. Soc. 2009. V. 131. -N.18.-P.6402−6411.
- Mishra N.N., Prasad T., Sharma N. et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review // Acta Microbiol. Immunol. Hung. 2007. V.54. — N.3. — P.201−235.
- Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention // Exp. Biol. Med.- 2004. V.229. N.7. — P.567−585.
- Moen M.D., Lyseng-Williamson K.A., Scott L.J. Liposomal amphotericin В: а review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections // Drugs. 2009. V.69. -N.3. — P.361−392.
- Mohan K.V., Muller J., Atreya C.D. Defective rotavirus particle assembly in lovastatin-treated MA 104 cells // Arch. Virol. 2008. V.153. — N.12. — P.2283−2290.
- Mohr J., Johnson M., Cooper T. et al. Current options in antifungal pharmacotherapy. 1 // Pharmacotherapy. 2008. V.28. -N.5. — P.614−645.
- Molinari G. Natural products in drug discovery: present status and perspectives // Adv. Exp. Med. Biol. 2009. V.655. — P. 13−27.
- Moller С., Slack M. Impact of new technologies for cellular screening along the drug value chain // Drug Discov. Today. 2010. V. l 5. — N.9−10. — P.384−390.
- Monnet D.L. Raising awareness about prudent use of antibiotics: a necessity for the European Union // Enferm. Infecc. Microbiol. Clin. 2010. V.28. — Suppl. 4. P. l-3.
- Moore R.D., Bartlett J.G., Gallant J.E. Association between Use of HMG. CoA Reductase Inhibitors and Mortality in HIV-infected Patients // PLoS One. -2011. V.6. N.7. — P. e21843. — Режим доступа: www.ncbi.nlm.nih.gov/pubmed/21 765 919.
- Morris M.I., Villmann M. Echinocandins in the management of invasive fungal infections, Part 2 // Am. J. Health Syst. Pharm. 2006. V.63. -N. 19. — P. 18 131 820.
- Moy T.I., Conery A.L., Larkins-Ford J. et al. High-throughput screen for novel antimicrobials using a whole animal infection model // ACS Chem. Biol. 2009. V.4. — N.7. — P.527−533.
- Moyad M.A., Klotz L.H. Statin Clinical Trial (REALITY) for Prostate Cancelan Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement // Urol. Clin. North Am. 2011. V.38. — N.3. — P.325−331.
- Murakawa S., Sakai K., Endo A. Isolation of 3 alpha-hydroxy-3,5-dihydro ML-236C (sodium salt) from paecilomyces viridis L-68 // J. Antibiot (Tokyo). 1994. V.47. -N.l. -P.108−109.
- Murray C.J., Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study // Lancet. 1997. V.349. — N.9061. — P. 12 691 276.
- Naeger-Murphy N., Pile J.C. Clinical indications for newer antifungal agents // J. Hosp. Med. 2009. V.4. — N.2. — P. 102−111.
- Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I // Circulation.-2003. V. 108.-N. 14. P. 1664−1672. (a)
- Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II // Circulation. 2003. V.108. — N. l5. — P. 1772−1778. (b)
- Nakakita, Y., Nakagawa M., Sakai H. Isolation of oligomycin A as a result of screening for antagonists of lipids // J. Antibiotics. 1980. V.33. — N.5. — P.514−516.
- Nakamura S. Total synthesis of the squalene synthase inhibitor zaragozic acid C // Chem. Pharm. Bull (Tokyo). -2005. V.53. N.l. — P. 1−10.
- Natesan S.K., Chandrasekar P.H., Alangaden G.J., Manavathu E.K. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro // Diagn. Microbiol. Infect Dis. 2008. V.60. — N.4. — P.369−373.
- Nedal A., Sletta H., Brautaset T. et al. Analysis of the mycosamine biosynthesis and attachment genes in the nystatin biosynthetic gene cluster of Streptomyces noursei ATCC 11 455 // Appl. Environ. Microbiol. -2007. V.73. -N.22. P.7400−7407.
- Neumann A., Baginski M., Czub J. How do sterols determine the antifungal activity of amphotericin B? Free energy of binding between the drug and its membrane targets // J. Am. Chem. Soc. 2010. V.132. -N.51. — P. 18 266−18 272.
- Netherland C., Thewke D.P. Rimonabant is a dual inhibitor of acyl CoA: cholesterol acyltransferases 1 and 2 // Biochem. Biophys. Res. Commun. -2010. V.398. N.4. — P.671−676.
- Nishida H., Ohnishi Y., Beppu Т., Horinouchi S. Evolution of gamma-butyrolactone synthases and receptors in Streptomyces // Environ. Microbiol. -2007. V.9. N.8. — P.1986−1994.
- Nosanchuk J.D. Current status and future of antifungal therapy for systemic mycoses // Recent Pat. Antiinfect. Drug Discov. 2006. V. 1. — N.l. — P.75−84.
- Nosanchuk J.D., Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds // Antimicrob. Agents Chemother. -2006. V.50.-N.l 1.-P.3519−3528.
- Novgorodov S.A., Gudz T.I., Mohr Yu.E. et al. ATP-synthase complex: the mechanism of control of ion fluxes induced by cumene hydroperoxide in mitochondria // FEBS Lett. 1989. V.247. — N.2. — P.255−258.
- Nucci M., Marr K.A. Emerging fungal diseases // Clin. Infect. Dis. -2005. V.41. -N.4. P.521−526.
- Odds F.C. Genomics, molecular targets and the discovery of antifungal drugs // Rev. Iberoam. Micol. 2005. V.22. — N.4. — P.229−237.
- Ogawa H., Hasumi K., Sakai K. et al. Pannorin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor produced by Chrysosporium раппогит/П. Antibiot (Tokyo). 1991. V.44. — N.7. — P.762−767.
- Ohshiro T., Matsuda D., Nagai K. et al. The selectivity of beauveriolide derivatives in inhibition toward the two isozymes of acyl-CoA: cholesterol acyltransferase // Chem. Pharm. Bull (Tokyo). 2009. V.57. — N.4. — P.377−381.
- Ohshiro T., Rudel L.L., Omura S., Tomoda H. Selectivity of microbial acyl-CoA: cholesterol acyltransferase inhibitors toward isozymes // J. Antibiot (Tokyo). 2007. V.60. — N. 1. — P.43−51.
- Okanishi M., Suzuki N., Furuta T. Variety of hybrid characters among recombinants obtained by interspecific protoplast fusion in streptomycetes // Biosci. Biotechnol. Biochem. 1996. V.60. — N.8. — P. 1233−1238.
- Okanishi M., Yamaura Y., Furuta T. Variety of intracellular products among recombinants obtained by interspecific protoplast fusion in streptomycetes // Biosci. Biotechnol. Biochem. 1997. V.61. — N.4. — P.748−751.
- Olano C., Mendez C., Salas J.A. Molecular insights on the biosynthesis of antitumour compounds by actinomycetes // Microb. Biotechnol. 2011. V.4. -N.2. — P.144−164.
- Omura S. Philosophy of new drug discovery // Microbiol. Rev. 1986. V.50. -N.3. — P.259−279.
- Omura S., Tanaka Y., Nakagawa A. et al. Irumamycin, a new antibiotic active against phytopathogenic fungi // J. Antibiot (Tokyo). 1982. V.35. — N.2. -P.256−257.
- Omura S., Tanaka Y., Takahashi Y. et al. Irumamycin, an antifungal 20-membered macrolide produced by a Streptomyces. Taxonomy, fermentation and biological properties//J. Antibiot (Tokyo). 1984. V.37. — N.12. — P. 1572−1578.
- Omura S., Tomoda H., Kumagai H. et al. Potent inhibitory effect of antibiotic 1233A on cholesterol biosynthesis which specifically blocks 3-hydroxy-3-methylglutaryl coenzyme A synthase // J. Antibiot (Tokyo). 1987. V.40. — N.9. -P.1356−1357.
- O’Sullivan J., Phillipson D.W., Kirsch D.R. et al. Lanomycin and glucolanomycin, antifungal agents produced by Pycnidiophora dispersa. I. Discovery, isolation and biological activity // J. Antibiot (Tokyo). 1992. V.45. -N.3. — P.306−312.
- Palacios D.S., Anderson T.M., Burke M.D. A post-PKS oxidation of the amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity // J. Am. Chem. Soc. 2007. V.129. — N.45.- P.13 804−13 805.
- Palchaudhuri R., Hergenrother P.J. Triphenylmethylamides (TPMAs): Structure-activity relationship of compounds that induce apoptosis in melanoma cells // Bioorg. Med. Chem. Lett. 2008. V. 18. — N.22. — P.5888−5891.
- Palchaudhuri R., Nesterenko V., Hergenrother P.J. The complex role of the triphenylmethyl motif in anticancer compounds // J. Am. Chem. Soc. 2008. V.130.-N.31.-P.10 274−10 281.
- Panda D., Rathinasamy K., Santra M.K., Wilson L. Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer // Proc. Natl. Acad. Sci. USA.- 2005. V.102. N.28. -P.9878−9883.
- Park J.K., Sakai K., Ogawa H. et al. Chrysosporin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase produced by Chrysosporium pannorum II J. Antibiot (Tokyo). 1993. V.46. — N.7. — P. 1170−1172.
- Pathania R., Brown E.D. Small and lethal: searching for new antibacterial compounds with novel modes of action // Biochem. Cell Biol. 2008. V.86. — N.2.- P.111−115.
- Pelaez F. The historical delivery of antibiotics from microbial natural products-can history repeat? // Biochem. Pharmacol. 2006. V.71. — N.7. — P.981−990.
- Pojer F., Ferrer J-L., Richard S.B. et al. Structural basis for the design of potent and species-specific inhibitors of 3-hydroxy-3-methylglutaryl CoA synthases // Proc. Natl. Acad. Sci. USA. -2006. V.103. N.31. — P. l 149 111 496.
- Ponpipom M.M., Girotra N.N., Bugianesi R.L. et al. Structure-activity relationships of CI and C6 side chains of zaragozic acid A derivatives // J. Med. Chem.- 1994. V.37.-N.23. P.4031−4051.
- Rahman H., Austin B., Mitchell W.J. et al. Novel anti-infective compounds from marine bacteria // Mar Drugs. 2010. V.8. — N.3. — P.498−518.
- Raina S., De Vizio D., Odell M. et al. Microbial quorum sensing: a tool or a target for antimicrobial therapy? // Biotechnol. Appl. Biochem. 2009. V.54. -N.2. — P.65−84.
- Rajnisz A., Solecka J., Kurzatkowski W. Properties of Saccharopolyspora erythraea strains after protoplast regeneration // Folia Microbiol (Praha). 2005. V.50. -N.l. -P.13−18.
- Ramsden N.L., Buetow L., Dawson A. et al. A structure-based approach to ligand discovery for 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase: a target for antimicrobial therapy // J. Med. Chem. -2009. V.52. N.8. — P.2531−2542.
- Rasko D.A., Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease //Nat. Rev. DrugDiscov. 2010. V.9. -N.2. -P.l 17−128.
- Rathinasamy K., Jindal B., Asthana J et al. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine // BMC Cancer. 2010. V. 10. — P.213.
- Recamier K.S., Hernandez-Gomez A., Gonzalez-Damian J., Ortega-Blake 1. Effect of membrane structure on the action of polyenes: I. Nystatin action incholesterol- and ergosterol-containing membranes // J. Membr. Biol. -2010. V.237. -N.l. P.31−40.
- Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. NCCLS Document M27-A. // NCCLS: Wayne, PA, 1997, — ISBN 1−56 238−328−0.
- Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard. NCCLS Document M38- A. // NCCLS: Wayne, PA, 2002. ISBN 1−56 238−470−8.
- Repko E.M., Maltese W.A. Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability // J. Biol. Chem. 1989. V.264. — N. 17. — P.9945−9952.
- Rohmer M. A mevalonate independent route to asoprenoid diphosphate // In «Comprehensive Natural Products Chemistry» Eds. D. Barton, K.Nakanishi. -Oxford: Pergamon, 1999. V.2. — P.45−67.
- Rohmer M., Knani M., Simonin P. et al. Isoprenoid biosynthesis in bacteria: A novel pathway for the early steps leading to isopentenyl diphosphate // Biochem. J. 1993. V.295. -N.2. — P.517−524.
- Ruiz B. Carbon source regulation of antibiotic production // J. Antibiot (Tokyo). 2010. V.63. -N.8. — P.442−459.
- Ruiz B., Chavez A., Forero A. et al. Production of microbial secondary metabolites: regulation by the carbon source // Crit. Rev. Microbiol. 2010. V.36. — N.2. — P.146−167.
- Ruiz-Camps I., Cuenca-Estrella M. Antifungals for systemic use // Enferm. Infecc. Microbiol. Clin. 2009. V.27. — N.6. — P.353−362.
- Saag M.S., Graybill R.J., Larsen R.A. et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America // Clin. Infect. Dis. 2000. V.30. N.4. -P.710−718.
- Sanchez S., Demain A.L. Metabolic regulation and overproduction of primary metabolites // Microb. Biotechnol. 2008. V.l. -N.4. — P.283−319.
- Sanchez S., Chavez A., Forero A. et al. Carbon source regulation of antibiotic production // J. Antibiot (Tokyo). 2010. V.63. — N.8. — P.442−459.
- Sasaki H., Hosokawa T., Sawada M., Ando K. Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity // J. Antibiot (Tokyo). 1973. V.26. — N. l 1. — P.676−680.
- Sawada M., Hosokawa T., Okutomi T., Ando K. Hypolipidemic property of ascofuranone//J. Antibiot (Tokyo). 1973. V.26. — N. l 1.-P.681−686.
- Schirmer A., Gadkari R., Reeves C.D. et al. Metagenomic analysis reveals diverse polyketide synthase gene clusters in microorganisms associated with the marine sponge Discodermia dissoluta II Appl. Environ. Microbiol. -2005. V.71. N.8. — P.4840−4849.
- Schneider P., Misiek M., Hoffmeister D. In vivo and in vitro production options for fungal secondary metabolites // Mol. Pharm. 2008. V.5. — N.2. -P.234−242.
- Schopfer U., Engeloch C., Hohn F. et al. Hypothesis-driven screening // Methods Mol. Biol. 2009. V.575. — P.297−316.
- Schwartz R.E., Dufresne C., Flor J.E. et al. Restricticin, a novel glycine-containing antifungal agent // J. Antibiot (Tokyo). 1991. V.44. — N.5. — P.463−471.
- Seco E.M., Fotso S., Laatsch H., Malpartida F. A tailoring activity is responsible for generating polyene amide derivatives in Streptomyces diastaticus var. 108//Chem. Biol.-2005. V.12.-N.10.-P.1093−1101.
- Seiki S., Frishman W.H. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia // Cardiol. Rev. 2009. V.17. -N.2. — P.70−76.
- SerizawaN., Nakagawa K., Hamano K. et al. Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B) // J. Antibiot (Tokyo). -1983. V.36. N.5. — P.604−607. (a)
- Serizawa N., Nakagawa K., Tsujita Y. et al. 3 alpha-Hydroxy-ML-236B (3 alpha-hydroxycompactin), microbial transformation product of ML-236B (compactin) // J. Antibiot (Tokyo). 1983. V.36. — N.5. — P.608−610. (b)
- SerizawaN., Nakagawa K., Tsujita Y. et al. 6 alpha-Hydroxy-iso-ML-236B (6 alpha-hydroxy-iso-compactin) and ML-236A, microbial transformation products of ML-236B // J. Antibiot (Tokyo). 1983. V.36. — N.7. — P.918−920. (c)
- Serizawa N., Serizawa S., Nakagawa K. et al. Microbial hydroxylation of ML-236B (compactin). Studies on microorganisms capable of 3 beta-hydroxylation of ML-236B // J. Antibiot (Tokyo). 1983. V.36. — N.7. — P.887−891. (d)
- Shellman Y.G., Ribble D., Miller L. et al. Lovastatin-induced apoptosis in human melanoma cell lines // Melanoma Res. 2005. V. 15. — N.2. — P.83−89.
- Shimada Y., Morita Т., Sugiyama K. Dietary eritadenine and ethanolamine depress fatty acid desaturase activities by increasing liver microsomal phosphatidylethanolamine in rats // J. Nutr. 2003. V.133. — N.3. — P.758−765.
- Shiomi M., Yamada S., Amano Y. et al. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/1 ipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions // Br. J. Pharmacol. 2008. V. l 54. — N.5. — P.949−957.
- Shord S.S., Chan L.N., Camp J.R. et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam // Br. J. Clin. Pharmacol. -2010. V.69. -N.2. P.160−166.
- Silva L., Coutinho A., Fedorov A., Prieto M. Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study // Biophys. J. 2006. V.90. — N. 10. — P.3625−3631.
- Singh S.B., Barrett J.F. Empirical antibacterial drug discovery—foundation in natural products // Biochem. Pharmacol. 2006. V.71. — N.7. — P. 1006−1015.
- Singh S.B., Pelaez F. Biodiversity, chemical diversity and drug discovery // Prog. Drug Res. 2008. V.65. — N. 141. — P. 143−174.
- Singh S.B., Young K. New antibiotic structures from fermentations // Expert Opin. Ther. Pat. -2010. V.20. -N.10. P.1359−1371.
- Sioud M., Baldacci G., Forterre P., de Recondo A.M. Antitumor drugs inhibit the growth ofhalophilic archaebacteria//Eur. J. Biochem. 1987. V. l69. -N.2. -P.231−236.
- Slawiriska A., Kandefer-Szerszeri M. The anticancer properties of statins // Postepy Hig Med. Dosw. (online). 2008. V.62. — P.393−404.
- Smondyrev A.M., Berkowitz M.L. Molecular dynamics simulation of the structure of dimyristoylphosphatidylcholine bilayers with cholesterol, ergosterol, and lanosterol // Biophys. J. 2001. V.80. N.4. — P. 1649−1658.
- Song Y., Lin F.Y., Yin F. et al. Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus // J. Med. Chem. 2009. V.52. -N.4. — P.976−988.
- SoppaJ. From genomes to function: haloarchaea as model organisms // Microbiology. 2006. V.152. — Pt.3. — P.585−590.
- Sunazuka Т., Hirose Т., Omura S. Efficient total synthesis of novel bioactive microbial metabolites//Acc. Chem. Res.-2008. V.41.-N.2. P.302−314.
- Sunazuka Т., Tsuzuki K., Kumagai H et al. Synthesis of 1233 A analogs and their inhibitory activity against hydroxymethylglutaryl coenzyme A synthase // J. Antibiot (Tokyo). 1992. V.45. — N.7. — P. l 139−1147.
- Sutherlin A., Hedl M., Sanchez-Neri B. et al. Enterococcus faecalis 3-hydroxy-3-methylglutaryl coenzyme A synthase, an enzyme of isopentenyl diphosphate biosynthesis // J. Bacteriol. 2002. V.184. -N.15. — P.4065−4070.
- Taoufiq Z., Pino P., N’dilimabaka N. et al. Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage // Malar J. -2011. V.10. -N.52. P.1−9. Режим доступа: http://www.malariajournal.eom/content/10/l/52.
- Tapia P. C.V. An update on antifungal susceptibility testing // Rev. Chilena Infectol. -2009. V.26. -N.2. -P.:144−150.
- Taylor P.L., Wright G.D. Novel approaches to discovery of antibacterial agents // Anim. Health Res. Rev. 2008. V.9. — N.2. — P.237−246.
- Tenchov В., Vescio E.M., Sprott G.D. et al. Salt tolerance of archaeal extremely halophilic lipid membranes // J. Biol. Chem. 2006. V.281. — N. l5. -P.10 016−10 023.
- Thompson C. J., Ward J. M., Hop wood D.A. Cloning of antibiotic resistance and nutritional genes in streptomycetes // J. Bacteriol. 1982. V.151. — N.2. -P.668−677.
- Thompson G.R. The proving of the lipid hypothesis // Curr. Opin. Lipidol. -1999. V.10. -N.3. P.201−205.
- Thompson G.R. Management of dyslipidaemia // Heart. 2004. V.90. — N.8. -P.949−955.
- Thompson G.R., Naoumova R.P. Novel lipid-regulating drugs // Expert Opin. Investig. Drugs. 2000. V.9. — N. l 1. — P.2619−2628.
- Thompson G.R., Catapano A., Saheb S. et al. Severe hypercholesterolemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe // Curr. Opin. Lipidol. 2010. V.21. — N.6. — P.492−498.
- Thompson G.R. 3rd, Cadena J., Patterson T.F. Overview of antifungal agents // Clin. Chest Med. 2009. V.30. -N.2. — P.203−215.
- Tierney K.J., Block D.E., Longo M.L. Elasticity and phase behavior of DPPC membrane modulated by cholesterol, ergosterol, and ethanol // Biophys. J. 2005. V.89. -N.4. — P.2481−2493.
- Tiwari K., Gupta R.K. Rare actinomycetes: a potential storehouse for novel antibiotics // Crit. Rev. Biotechnol. 2011 May 27. — Epub. ahead of print -Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/21 619 453.
- Tomoda H., Huang X-H., Cao J. et al. Inhibition of acyl-CoA: cholesterol acyltransferase activity by cyclodepsipeptide antibiotics // J. Antibiot (Tokyo). -1992. V.45. -N.10. P.1626−1632. (a)
- Tomoda H., Kumagai H., Tanaka H., Omura S. Specific binding of beta-lactone 1233A to 3-hydroxy-3-methylglutaryl-coenzyme A synthase // J. Antibiot (Tokyo). 1993. V.46. -N.5. — P.872−874.
- Tomoda H., Kumagai H., Tanaka H., Omura S. F-244 specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A synthase // Biochim. Biophys. Acta.1987. V.922. N.3. — P.351−356.
- Tomoda H., Nishida H., Huang X-H. et al. New cyclodepsipeptides, enniatins D, E and F produced by Fusarium sp. F0−1305 // J. Antibiot (Tokyo). 1992. V.45. -N.8. — P. 1207−1215. (b)
- Tournu H., Serneels J., Van Dijck P. Fungal pathogens research: novel and improved molecular approaches for the discovery of antifungal drug targets // Curr. Drug Targets. 2005. V.6. — N.8. — P.909−922.
- Trenin A.S. Modern microbiological method in monitoring growth and secondary metabolism of microbial strains. // 7-th Intern. Congress on Rapid Methods and Automation in Microbiology and Immunology, 12−15 Sept. 1993. -London, GB, 1993. Abstr.P.43.
- Trenin A.S. Automation of microbiological methods in screening of Actinomycetes producing biologically active substances. // Theses of the 9-th International Symposium on the Biology of Actinomycetes, 10−15 July 1994. -Moscow, 1994. P. 172. (a)
- Trenin A.S. Microbial test system for screening of secondary metabolites inhibiting cholesterol biosynthesis. // International Conference on Microbial Secondary Metabolism, 5−8 Oct. 1994. Interlaken, 1994. — Abstr.P.4. (b)
- Tsunakawa M., Kotake C., Yamasaki T. et al. New antiviral antibiotics, cycloviracins B1 and B2. II. Structure determination // J. Antibiot (Tokyo).1992. V.45. -N.9. P. 1472−1480.
- Twentyman P.R., Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensittivity // Br. J. Cancer. -1987. V.56. N.3. — P.279−285.
- Uotani K., Naganawa H., Kondo S. et al. Structural studies on ebelactone A and B, esterase inhibitors produced by actinomycetes // J. Antibiot (Tokyo).1982. V.35. N. l 1. — P. 1495−1499.
- Ura H., Obara Т., Nishino N. et al. Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene // Jpn. J. Cancer Res. 1994. V.85. — N.6. — P.633−638.
- Van der Pyl D., Inokoshi J., Shiomi K. et al. Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin // J. Antibiot (Tokyo). 1992. V.45. -N.l 1. — P.1802−1805.
- Ventosa A., Nieto J.J., Oren A. Biology of moderately halophilic aerobic bacteria // Microbiol. Mol. Biol. Rev. 1998. V.62. — N.2. — P.504−544.
- Walker L.A., Gow N.A., Munro C.A. Fungal echinocandin resistance // Fungal Genet. Biol. 2010. V.47. -N.2. -P.l 17−126.
- Walker L.A., Munro C.A., de Bruijn I. et al. Stimulation of chitin synthesis rescues Candida albicans from echinocandins // PLoS Pathog. 2008. V.4. — N.4. — P. el 40. — Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/18 389 063
- Wang I.K., Lin-Shiau S.Y., Lin J.K. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells // Pharmacol. Toxicol. 2000. V.86. — N.2. — P.83−91.
- Wanke M., Skorupinska-Tudek K., Swiezewska E. Isoprenoid biosynthesis via 1 -deoxy-D-xylulose 5-phosphate/2-C-methyl-D-erythritol 4-phosphate (DOXP/MEP) pathway // Acta Biochim. Pol. 2001. V.48. -N.3. — P.663−672.
- Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective // Crit. Rev. Immunol. 1999. V.19. — N1. — P.65−96.
- Weber J. ATP synthase the structure of the stator stalk // Trends Biochem. Sci. — 2007. V.32. — N.2. — P.53−56.
- Wejde J., Hjertman M., Carlberg M. et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? // J. Cell Biochem. 1998. V.71. -N.4. — P.502−514.
- Wilding E.I., Brown J.R., Bryant A.P. et al. Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci // J. Bacteriol. 2000. V. l 82. -N.15. — P.4319−4327. (a)
- Wilding E.I., Kim D.Y., Bryant A.P. et al. Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus II J. Bacteriol. -2000. V. l82. N.18. — P.5147−5152. (b)
- Wilson I.D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring // Proc. Natl. Acad. Sci. USA.- 2009. V. l06. N.34. — P. 1 418 714 188.
- Wong W.W., Tan M.M., Xia Z. et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin // Clin. Cancer Res. -2001. V.7. -N.7. P.2067−2075.
- Wong W.W., Clendening J.W., Martirosyan A. et al. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma // Mol. Cancer Ther. 2007. V.6. — N.6. — P.1886−1897.
- Yamamoto I., NakagawaM., Hayakawa Y. et al. Hydroxychlorothricin, a new antitumor antibiotic //J. Antibiot (Tokyo). 1987. V.40. — N10. — P. 1452−1454.
- Yamashita H., Tsubokawa S., Endo A. Microbial hydroxylation of compactin (ML-236B) and monacolin K // J. Antibiot (Tokyo). 1985. V.38. -N.5. — P.605−609.
- Yamazaki H., Omura S., Tomoda H. 6'-Hydroxy-3'-methoxy-mitorubrin, a new potentiator of antifungal miconazole activity, produced by Penicillium radicum FKI-3765−2 // Chem. Pharm. Bull. (Tokyo). 2010. V.58. — N.6. — P.829−832.
- Yang P.W., Li M.G., Zhao J.Y. et al. Oligomycins A and C, major secondary metabolites isolated from the newly isolated strain Streptomyces diastaticus II Folia Microbiol. (Praha). -2010. V.55.-N.l. -P.10−16.
- Yarbrough G.G., Taylor D.P., Rowlands R.T. et al. Screening microbial metabolites for new drugs-theoretical and practical issues // J. Antibiot (Tokyo). -1993. V.46. N.4. — P.535−544.
- Yim G., Wang H.H., Davies J. Antibiotics as signalling molecules // Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2007. V.362. — N.1483. — P. l 195−1200.
- Zanella F., Lorens J.B., Link W. High content screening: seeing is believing. Trends Biotechnol. 2010. V.28. -N.5. -P.237−245.
- Zhang B., Watts K.M., Hodge D. et al. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling // Biochemistry. 2011. V.50. — N. l7. — P.3570−3577.
- Zhao G., Lin X., Dou W. et al. Use of the smart tongue to monitor mold growth and discriminate between four mold species grown in liquid media // Anal. Chim. Acta. 2011. V.690. — N.2. — P.240−247.
- Zhou Q., Liao J.K. Rho kinase: an important mediator of atherosclerosis and vascular disease // Curr. Pharm. Des. 2009. V. 15. — N.27. — P.3108−3115. (a)
- Zhou Q., Liao J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy // Curr. Pharm. Des. 2009. V.15. — N.5. — P.467−478. (b)
- Zhou Q., Liao J.K. Pleiotropic effects of statins. Basic research and clinical perspectives // Circ. J. 2010. V.74. — N.5. — P.818−826.
- Zotchev S.B. Polyene macrolide antibiotics and their applications in human therapy // Curr. Med. Chem. 2003. V.10. — N.3. — P.211−223.